NEW YORK – Qiagen said on Tuesday that it has received a CE-IVD mark for its Artus SARS-CoV-2 Prep&Amp UM Kit for high-throughput PCR-based COVID-19 testing.
The kit is now commercially available in the EU and other markets accepting the CE-IVD mark, and Qiagen has submitted an Emergency Use Authorization application for the assay to the US Food and Drug Administration.
The Quantum Startup Foundry (QSF) at the University of Maryland brings together the resources needed—physical and virtual—to support entrepreneurs and startups in accelerating quantum technologies’ time to market. QSF will bring entrepreneurs together with industry and government customers, investors, technical mentors, leading-edge research and IP, and quantum-specific infrastructure (equipment, tools, facilities). Located in the Washington, DC metro area, QSF offers the perfect landing and launch spot for quantum companies.
A group of top lawmakers of both parties in both chambers of Congress on Wednesday reintroduced legislation that aims to spend $110 billion on vital technologies to sustain American leadership and spur competitiveness against China.
The draft bill, known as the Endless Frontier Act, championed by Senate Majority Leader Charles E. Schumer, D-N.Y., and Sen. Todd Young, R-Ind., is matched by a companion bill in the House by Reps. Ro Khanna, D-Calif., and Mike Gallagher, R-Wis.
The Matan Cos. will add biotech manufacturing and research space to one of its existing office campuses in Germantown to meet the surge in demand from local life sciences firms.
The new construction is slated for the Milestone Business Park, located just off Interstate 270 at the Father Hurley Boulevard exit, the Frederick-based developer told the Washington Business Journal. Matan plans to add three new buildings totaling 532,000 square feet, constructing them on some of the site’s ample parking lots and rebranding the campus as “Milestone Innovation Park.”
Image: Matan Cos. plans to add three new biotech-focused manufacturing and research buildings at its Milestone office park in Germantown. HIGH ROCK STUDIOS
Did you miss our 3-day Workshop featuring experts from NIH, HHS, NCI, NSF, USAMRDC, NIA, MTech, BHI, and others? Videos and Slide decks are now available by visiting http://www.
AURP and BHI Report Centers on Critical Factors Cultivating BioHealth Communities of Innovation Nationally & Supported Growth of BioHealth Capital Region
Tucson, AZ; Rockville, MD; College Park, MD, April 21, 2021 – The Association of University Research Parks (AURP) and BioHealth Innovation (BHI) today announce publication of Creating Communities of Life Science Innovation in the U.S.: History of Critical Factors That Helped the BioHealth Capital Region Emerge in the Journal of Commercial Biotechnology, (Vol 26, No. 1, March 2021).
In this new article, AURP CEO Brian Darmody outlines the history of critical policy factors leading to the growth of the bio-economy in the U.S. BHI CEO and President Richard Bendis discusses specific leadership and other factors in the Capital Region of Washington, DC, Maryland, and Virginia. Policies and trends such as the Land Grant Act, Bayh-Dole Act, NIH’s founding, growth of the venture financing industry, and the emergence of research parks and innovation districts and related factors also are discussed. National bio cluster rankings from JLL, CBRE, and GEN are included as well as overviews of Boston, New York, Philadelphia and DC/MD/VA life science regions from GEN.
With its unique system of intramural and extramural research programs, funding for academic and corporate product development, along with its supporting foundations, the National Institutes of Health (NIH) has created a vibrant public “innovation ecosystem” that has changed not only the face of healthcare, but has also led to the creation of the biotech industry in the U.S. Whether your interest in the overall healthcare environment is scientific, medical, educational or commercial, there is something here for you.
Image: Dr Joseph J.Kinyoun, NIH Founder – https://www.ncbi.nlm.nih.gov
ROCKVILLE, Md., April 19, 2021 /PRNewswire/ — Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Rhonda Henry has joined the company as President of Emmes BioPharma.
“Naming a leader of our biopharma group is a major, positive step in our strategy to expand and diversify our business,” said Dr. Christine Dingivan, Chief Executive Officer of Emmes.
It might surprise you to learn that many of the innovations deployed to counter the coronavirus were once obscure Pentagon-funded projects to defend soldiers from contagious diseases and biological weapons. The life-saving vaccine developed in record time owes a debt to these programs. To learn more, we met the man who has been leading the rapid vaccine effort, retired Colonel Matt Hepburn. An army infectious disease physician, he spent years with the secretive defense advanced research projects agency or DARPA, working on technology he hopes will ensure COVID-19 is the last pandemic.
As the CEO of a 2,000-plus person Maryland-based company involved in the COVID-19 response, I have a high tolerance for the obligations that come with it — like spending endless hours trying to explain complicated manufacturing processes to reporters who just learned we existed. Or battling back the misinformation that is used to find fault with the people who are the spine of our nation’s world-leading response to this pandemic.
Image: Manufacturing associates work on a COVID-19 vaccine in one of four flexible manufacturing suites at Emergent BioSolutions’ Bayview facility. (Jerry Jackson/Baltimore Sun) (Jerry Jackson/Baltimore Sun)
